AU2021284380A1 - Compounds and methods for the treatment of eye disorders - Google Patents

Compounds and methods for the treatment of eye disorders Download PDF

Info

Publication number
AU2021284380A1
AU2021284380A1 AU2021284380A AU2021284380A AU2021284380A1 AU 2021284380 A1 AU2021284380 A1 AU 2021284380A1 AU 2021284380 A AU2021284380 A AU 2021284380A AU 2021284380 A AU2021284380 A AU 2021284380A AU 2021284380 A1 AU2021284380 A1 AU 2021284380A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021284380A
Other languages
English (en)
Inventor
Chris Burns
Eric Daniels
Darren Kelly
Michelle PAPADIMITRIOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OccuRx Pty Ltd
Original Assignee
OccuRx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901858A external-priority patent/AU2020901858A0/en
Application filed by OccuRx Pty Ltd filed Critical OccuRx Pty Ltd
Publication of AU2021284380A1 publication Critical patent/AU2021284380A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021284380A 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders Pending AU2021284380A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901856 2020-06-05
AU2020901858 2020-06-05
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
AU2021284380A1 true AU2021284380A1 (en) 2023-01-19

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021284380A Pending AU2021284380A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Country Status (11)

Country Link
US (1) US20230270703A1 (https=)
EP (1) EP4161527A4 (https=)
JP (1) JP2023529845A (https=)
KR (1) KR20230024331A (https=)
CN (1) CN116033901A (https=)
AU (1) AU2021284380A1 (https=)
BR (1) BR112022024728A2 (https=)
CA (1) CA3185849A1 (https=)
IL (1) IL298733A (https=)
MX (1) MX2022015327A (https=)
WO (2) WO2021247900A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018314A2 (pt) * 2021-03-17 2023-10-31 Occurx Pty Ltd Compostos para o tratamento de distúrbios e sais e polimorfos dos mesmos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
KR19990082523A (ko) * 1996-02-15 1999-11-25 간자와 무츠와 혈관생성 억제제
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
CN1252718A (zh) * 1997-04-18 2000-05-10 橘生药品工业株式会社 预防或治疗与视网膜色素上皮细胞过度增殖相关的疾病的药剂
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
NZ609144A (en) * 2010-11-24 2014-08-29 Occurx Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
EP4161527A4 (en) 2024-06-26
US20230270703A1 (en) 2023-08-31
KR20230024331A (ko) 2023-02-20
JP2023529845A (ja) 2023-07-12
IL298733A (en) 2023-02-01
MX2022015327A (es) 2023-02-22
WO2021247900A1 (en) 2021-12-09
CA3185849A1 (en) 2021-12-09
BR112022024728A2 (pt) 2023-03-07
WO2021247901A1 (en) 2021-12-09
CN116033901A (zh) 2023-04-28
EP4161527A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
US20100120873A1 (en) Prophylactic or therapeutic agent for age-related macular degeneration
JP2020521002A (ja) テトラメチルピラジンニトロン誘導体の糖尿病合併症疾患の予防と治療における応用
RU2477132C2 (ru) Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
TW201444800A (zh) ｛［１－氰基－５－（４－氯苯氧基）－４－羥基－異喹啉－３－羰基］－胺基｝－乙酸之晶形
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
AU2021284380A1 (en) Compounds and methods for the treatment of eye disorders
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
CN120713906A (zh) 用于治疗代谢失调的组合物和方法
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
JP2012006918A (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
JP2023501967A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
KR20160113720A (ko) 황 함유 모이어티를 포함하는 당 유도체 및 이의 제조 방법 및 mps iiic의 치료를 위한 이의 사용 방법
CN113260612B (zh) 用于治疗或预防肌营养不良症的化合物及其在医药用途中的治疗、改善或预防用衍生物
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
KR20210141203A (ko) 에르도스테인 유도체 및 이를 함유하는 약학 조성물
US20110224200A1 (en) Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
US9579309B2 (en) Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient
KR20210046115A (ko) 니아신 유도체 및 이를 함유하는 약학 조성물
KR20230156931A (ko) 질병의 치료를 위한 화합물 및 이의 염 및 다형체
CN115557898A (zh) 一种咪唑类化合物、其中间体及应用
HK40049529A (en) Compounds for treatment or prevention of muscular dystrophy and derivatives for treatment, amelioration or prevention in medical use thereof
JPWO2010047369A1 (ja) 糖尿病性腎症の治療剤
CN116407554A (zh) 降低靶向抗肿瘤药物对肠道损伤的药物及其应用
TW201206433A (en) Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation